Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVIR NASDAQ:IOVA NASDAQ:RXRX NASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$4.57-16.9%$5.62$2.45▼$6.45$440.15M0.38266,131 shs971,366 shsIOVAIovance Biotherapeutics$3.66+2.8%$3.79$1.64▼$5.63$1.59B0.6916.02 million shs7.88 million shsRXRXRecursion Pharmaceuticals$3.05-3.2%$3.36$2.80▼$7.18$1.67B1.0512.48 million shs13.56 million shsSNDXSyndax Pharmaceuticals$20.89+2.4%$23.04$8.58▼$25.59$1.81B0.411.81 million shs1.54 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals-16.91%-19.12%-19.96%+5.54%+73.76%IOVAIovance Biotherapeutics+2.81%-10.51%+5.78%+45.24%+104.47%RXRXRecursion Pharmaceuticals-3.17%-11.08%-10.82%-14.80%-32.37%SNDXSyndax Pharmaceuticals+2.35%+1.16%-13.86%-1.18%+105.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$4.57-16.9%$5.62$2.45▼$6.45$440.15M0.38266,131 shs971,366 shsIOVAIovance Biotherapeutics$3.66+2.8%$3.79$1.64▼$5.63$1.59B0.6916.02 million shs7.88 million shsRXRXRecursion Pharmaceuticals$3.05-3.2%$3.36$2.80▼$7.18$1.67B1.0512.48 million shs13.56 million shsSNDXSyndax Pharmaceuticals$20.89+2.4%$23.04$8.58▼$25.59$1.81B0.411.81 million shs1.54 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals-16.91%-19.12%-19.96%+5.54%+73.76%IOVAIovance Biotherapeutics+2.81%-10.51%+5.78%+45.24%+104.47%RXRXRecursion Pharmaceuticals-3.17%-11.08%-10.82%-14.80%-32.37%SNDXSyndax Pharmaceuticals+2.35%+1.16%-13.86%-1.18%+105.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVIRAtea Pharmaceuticals 2.50Moderate BuyN/AN/AIOVAIovance Biotherapeutics 2.30Hold$8.43130.29% UpsideRXRXRecursion Pharmaceuticals 2.20Hold$9.20201.64% UpsideSNDXSyndax Pharmaceuticals 2.92Moderate Buy$42.55103.66% UpsideCurrent Analyst Ratings BreakdownLatest AVIR, RXRX, IOVA, and SNDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026SNDXSyndax Pharmaceuticals UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$38.00 ➝ $37.005/7/2026IOVAIovance Biotherapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$16.00 ➝ $14.005/7/2026RXRXRecursion Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/1/2026SNDXSyndax Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$35.00 ➝ $37.004/30/2026RXRXRecursion Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$11.00 ➝ $10.004/21/2026RXRXRecursion Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026AVIRAtea Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026IOVAIovance Biotherapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.004/6/2026IOVAIovance Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/1/2026SNDXSyndax Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $34.003/31/2026SNDXSyndax Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$45.00 ➝ $43.00(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVIRAtea PharmaceuticalsN/AN/AN/AN/A$3.53 per shareN/AIOVAIovance Biotherapeutics$263.50M6.20N/AN/A$1.62 per share2.26RXRXRecursion Pharmaceuticals$74.68M21.64N/AN/A$1.93 per share1.58SNDXSyndax Pharmaceuticals$172.35M10.74N/AN/A$0.47 per share44.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVIRAtea Pharmaceuticals-$158.35M-$1.94N/AN/AN/AN/A-53.22%-48.44%N/AIOVAIovance Biotherapeutics-$390.98M-$0.95N/AN/AN/A-123.92%-50.17%-38.77%N/ARXRXRecursion Pharmaceuticals-$644.76M-$1.20N/AN/AN/A-842.95%-54.33%-40.60%N/ASNDXSyndax Pharmaceuticals-$285.42M-$2.79N/AN/AN/A-111.88%-256.65%-45.25%N/ALatest AVIR, RXRX, IOVA, and SNDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026AVIRAtea Pharmaceuticals-$0.60-$0.57+$0.03-$0.57$22.42 millionN/A5/7/2026Q1 2026IOVAIovance Biotherapeutics-$0.19-$0.19N/A-$0.19$77.84 million$71.43 million5/6/2026Q1 2026RXRXRecursion Pharmaceuticals-$0.30-$0.22+$0.08-$0.22$15.78 million$6.47 million4/30/2026Q1 2026SNDXSyndax Pharmaceuticals-$0.59-$0.48+$0.11-$0.48$69.76 million$64.86 million3/5/2026Q4 2025AVIRAtea Pharmaceuticals-$0.49-$0.57-$0.08-$0.57N/AN/A2/26/2026Q4 2025SNDXSyndax Pharmaceuticals-$0.64-$0.78-$0.14-$0.78$64.75 million$68.73 million2/25/2026Q4 2025RXRXRecursion Pharmaceuticals-$0.28-$0.21+$0.07-$0.21$24.56 million$35.54 million2/24/2026Q4 2025IOVAIovance Biotherapeutics-$0.22-$0.18+$0.04-$0.18$81.61 million$86.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/ARXRXRecursion PharmaceuticalsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVIRAtea PharmaceuticalsN/A7.827.82IOVAIovance BiotherapeuticsN/A3.603.15RXRXRecursion Pharmaceuticals0.015.475.47SNDXSyndax Pharmaceuticals8.265.475.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVIRAtea Pharmaceuticals86.67%IOVAIovance Biotherapeutics77.03%RXRXRecursion Pharmaceuticals89.06%SNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAVIRAtea Pharmaceuticals18.10%IOVAIovance Biotherapeutics7.80%RXRXRecursion Pharmaceuticals8.43%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVIRAtea Pharmaceuticals7080.03 million65.54 millionOptionableIOVAIovance Biotherapeutics500446.50 million411.68 millionOptionableRXRXRecursion Pharmaceuticals400529.91 million485.23 millionOptionableSNDXSyndax Pharmaceuticals11088.61 million84.98 millionOptionableAVIR, RXRX, IOVA, and SNDX HeadlinesRecent News About These CompaniesSyndax Pharmaceuticals (NASDAQ:SNDX) Price Target Cut to $37.00 by Analysts at UBS Group22 minutes ago | americanbankingnews.comSyndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin InhibitionMay 12 at 10:31 AM | globenewswire.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Moderate Buy" from BrokeragesMay 12 at 2:32 AM | americanbankingnews.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 6, 2026 | globenewswire.comSyndax Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 5, 2026 | seekingalpha.comBiotech Momentum Builds As Syndax Pharmaceuticals Draws Market AttentionMay 5, 2026 | kalkinemedia.comKBank of America Securities Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX)May 5, 2026 | theglobeandmail.comHC Wainwright Has Optimistic Outlook of SNDX Q2 EarningsMay 5, 2026 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst UpgradeMay 4, 2026 | marketbeat.comHC Wainwright Has Bullish Outlook for SNDX FY2030 EarningsMay 4, 2026 | americanbankingnews.comHC Wainwright Has Optimistic Outlook of SNDX FY2030 EarningsMay 4, 2026 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 7.1% - Should You Sell?May 3, 2026 | americanbankingnews.comSyndax Slide Puts Nasdaq Index Biotech in FocusMay 2, 2026 | kalkinemedia.comKSyndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ...May 2, 2026 | finance.yahoo.comSyndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain Traction - What’s Really Shifting?May 2, 2026 | finance.yahoo.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 7.1% - Time to Sell?May 1, 2026 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $37.00May 1, 2026 | marketbeat.comSyndax: Q1 Earnings SnapshotApril 30, 2026 | stamfordadvocate.comSSyndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comSyndax Pharmaceuticals Q1 Earnings Call HighlightsApril 30, 2026 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Issues Quarterly Earnings ResultsApril 30, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVIR, RXRX, IOVA, and SNDX Company DescriptionsAtea Pharmaceuticals NASDAQ:AVIR$4.57 -0.93 (-16.91%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$4.57 0.00 (0.00%) As of 05/13/2026 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Iovance Biotherapeutics NASDAQ:IOVA$3.66 +0.10 (+2.81%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$3.66 -0.01 (-0.14%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Recursion Pharmaceuticals NASDAQ:RXRX$3.05 -0.10 (-3.17%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$3.05 0.00 (0.00%) As of 04:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Syndax Pharmaceuticals NASDAQ:SNDX$20.89 +0.48 (+2.35%) As of 05/13/2026 04:00 PM EasternSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Upside Expands as AI Feedback Loop Intensifies Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? D-Wave Earnings Looked Weak, But Investors May Be Missing This A Quantum Shift: Why Speculative Money Is Ditching AI Plug Power Flips The Switch On Profitability Reading the Stripes: Is The Industrial Recession Over? How Bad Could Tesla’s Cybertruck Recall Be for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
